Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.

@article{Karanika2017TargetingDD,
  title={Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.},
  author={Styliani Karanika and T Karantanos and Likun Li and Jianxiang Wang and SangHee Ko Park and Guang Yang and Xuemei Zuo and Jian H. Song and Sankar N. Maity and Ganiraju C Manyam and Bradley M. Broom and Ana Aparicio and Gary E. Gallick and P. Brunny Troncoso and Paul G. Corn and Nora Navone and Wei Zhang and Shuhua Li and Timothy C Thompson},
  journal={Cell reports},
  year={2017},
  volume={18 8},
  pages={1970-1981}
}
Cell division cycle 6 (CDC6), an androgen receptor (AR) target gene, is implicated in regulating DNA replication and checkpoint mechanisms. CDC6 expression is increased during prostate cancer (PCa) progression and positively correlates with AR in PCa tissues. AR or CDC6 knockdown, together with AZD7762, a Chk1/2 inhibitor, results in decreased TopBP1-ATR… CONTINUE READING